echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Obtained clinical understanding of HDAC inhibitor research and development status from HG146

    Obtained clinical understanding of HDAC inhibitor research and development status from HG146

    • Last Update: 2021-07-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com


















    4.
    Novartis's Farydak ((generic name: Panobinostat, Pabirestat)


    Farydak, approved by the FDA in February 2015, combined bortezomib and dexamethasone to treat multiple myeloma (and has received at least two previous treatments)
    .
    The approval is based on PFS (Progress-Free Survival) data and accelerated approval and listing
    .
    However, there is a black box warning, indicating that the drug has the risk of serious diarrhea and cardiac ischemic events.
    It is the fourth HDAC inhibitor approved by the FDA for marketing
    .


    5.
    Microchip's Chidamide


    The only HDAC inhibitor on the market in China is Chipamine's Chidamide (trade name: Epdaza), which is an oral, subtype selective HDAC inhibitor (for Class I HDAC 1, 2, and 2).
    3 subtypes and 10 subtypes of category IIb), approved in China in December 2014, are suitable for relapsed or refractory peripheral T-cell lymphomas that have received at least one systemic chemotherapy in the past
    .


    What are the advantages of HG146?


    The HDAC inhibitors currently on the market can be divided into two categories.
    The first category is non-selective pan-HDAC inhibitors.
    The indications are mainly peripheral T-cell lymphoma and relapsed multiple myeloma and other hematomas; the second category is specific Selective inhibitors of HDAC subtypes, such as Chidamide
    .
    The second category currently shows a good effect on a variety of solid tumors, and the market prospect is relatively broad
    .


    HG146 is a targeted therapy for HDACI/IIb, which is more specific than pan-HDAC inhibitors, and is expected to reduce the side effects of the drug and improve the therapeutic effect
    .
    The approval of the clinical study of HG146 solid tumors will help the further advancement of clinical trials and provide new treatment methods for solid tumor indications
    .


    In addition to the approved HDAC inhibitors, there are many drugs under research in this field.
    The dosage forms developed are mainly oral.
    The therapeutic areas include hematoma and solid tumors, as well as diseases in other fields
    .


    Partially organized according to public information


    HDAC is inextricably linked with tumorigenesis and immunity.
    In-depth study of its mechanism will help us understand the disease itself more deeply
    .
    Although the indications of HDAC inhibitors are mainly focused on blood diseases, their own role in the disease determines that they can go further
    .


    The indications of products currently on the market are mostly cutaneous T-cell lymphoma, peripheral T-cell lymphoma and multiple myeloma, and most of the products are undergoing clinical trials for new indications, such as breast cancer and non-small cell lung cancer.
    , Pancreatic cancer, etc.
    , with the deepening of research, the scope of its indications may increase.
    For example, the old Merck brand Zolinza mentioned above has carried out research on dormant HIV
    .


     Reference source:


    1.
    Minucci S, Pelicci PG.
    Histone deacetylase inhibitors and the promise of epigenetic(and more)treatments for cancer[J].
    Nat Rev Cancer, 2006, 6(1): 38-51.


    2.
    Peng X, et al.
    Eur J Med Chem.
    2020 Dec 15;208:112831.


    3.
    A Review of Progress in Histone Deacetylase 6 Inhibitors Research: Structural Specificity and Functional Diversity.

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.